替罗非班在急性冠状动脉综合征的应用效果研究  

Whether tirofiban in acute coronary syndrome application effect study

作　　者：方毅[1] 陈家林[1] 

机构地区：[1]深圳市第二人民医院心内科,518035

出　　处：《中国实用医药》2013年第20期75-76,共2页China Practical Medicine

摘　　要：目的探讨早期应用替罗非班在介入治疗的急性冠状动脉综合征患者中应用效果。方法应用随机数字表法将本院心内科2010年2月至2013年2月收治的100例急性冠状动脉综合征患者分为A组和B组,A组患者在经皮冠状动脉腔内成形术开始时使用替罗非班。B组患者在经皮冠状动脉腔内成形术前12～24h开始使用替罗非班,比较两组患者各项临床指标。结果 7d后,B组患者血浆C-反应蛋白、心肌肌钙蛋白I和血清肌酸激酶同工酶明显低于A组患者的,差异有统计学意义(P<0.05),B组患者急性再发心梗、梗死后心绞痛、心律失常、心力衰竭、出院前死亡和出血发生率差异无(P>0.05)。结论早期应用替罗非班在介入治疗的急性冠状动脉综合征患者中应用临床疗效确切,安全高效,不良反应少。Objective To investigate the early application of whether tirofiban in acute coronary artery interventional therapy of syndrome patients results. Methods Using random number table,100 cases of acute coronary artery in our hospital from 2010 February to 2013 February in Department of Cardiology were syndrome patients were divided into group A and group B,group A patients in percutaneous transluminal coronary angioplasty starting with whether tirofiban. Group B patients in percutaneous transluminal coronary angioplasty before 12～24 hours began to use whether tirofiban,compared two groups of patients with various clinical indicators. Results 7 days later,group B patients plasma Creactive protein,troponin I and creatine kinase isoenzyme was significantly lower than that in A group,there was significant difference （P 0.05）,acute B patients of recurrent myocardial infarction,angina after myocardial infarction,arrhythmia,heart failure,died before discharge and bleeding rate was not significantly different property （P 0.05）. Conclusion Early application of whether tirofiban in acute coronary artery interventional therapy of syndrome in patients with clinical efficacy, safety and high efficiency,less adverse reaction.

关 键 词：替罗非班 急性冠状动脉综合征 临床疗效 

分 类 号：R541.4[医药卫生—心血管疾病]